Several recent steps move the closure toward commercialization:
· New studies confirm the system’s usability and performance
· Design now finalized and preparations for industrialization underway
· Multiple new features set a new standard for luer lock closure systems
Ravensburg, January 15, 2026: Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has completed several important steps in the ongoing development and upcoming launch of V-OVS® next.
Developed from extensive
market feedback, this new closure system will feature several important
updates: intuitive handling, innovative functionality and a premium design,
that fits a wide range of syringe formats. Together these advances will further
enhance the protection and usability V-OVS® next offers for applications
across a broad range of markets such as ophthalmology, aesthetic injectables,
diluents, and biologics. Unveiled at PharmaPack 2025 and met with significant
industry interest, the closure has since taken multiple key steps toward
commercial readiness in 2027.
After a robust, multi-cycle
development process, Vetter has finalized the design of V-OVS® next
and initiated industrialization. As part of that process, Vetter will provide
its primary syringe glass suppliers with NFHU materials for further
implementation and testing across a range of syringe formats.
“With the first biopharma
customers already giving positive feedback, we’re excited to see market uptake
by some glass suppliers,” says Lars Hahn, Senior Vice President Global Sales
Organization at Vetter. “We’ve already had successful conversations with
multiple value chain partners and received consistently encouraging responses
that reinforce our confidence in this launch.”
Vetter has completed two more
important verification steps of its own: After successfully completing a first
Human Factors study earlier in 2025, a second Human Factors study and a key
Functional Study have both delivered positive results for V-OVS® next.
While the earlier evaluation
focused on product and user-related feedback, the second Human Factors study additionally
included a use related risk analysis to confirm that V-OVS® next enables
safe and effective handling. After evaluating the closure system’s usability
and comparing it with the original V-OVS® closure, study
participants confirmed: V-OVS® next is a user-friendly design
that offers an enhanced user experience with a differentiating look and feel.
In addition, Vetter evaluated
the structural performance of V-OVS® next during
manufacturing and handling. First tests demonstrated that V-OVS® next
further improves upon the performance of the existing V-OVS®, supports
intuitive handling, and reduces the likelihood of misuse.
“Our goal was to combine
safety, usability, and design in a way that truly benefits the user of the
system,” says Dr. Claus Feussner, Senior Vice President Development Service at
Vetter. “The positive results from both usability and performance evaluations
confirm that V-OVS® next delivers on these objectives.”
With these milestones achieved,
Vetter will continue to advance V-OVS® next down its pathway toward
launch. Industrialization is on track and commercialization is scheduled for
2027. Post-launch, Vetter will continue to offer both V-OVS®
and V-OVS® next, expanding its portfolio of solutions for
customers’ syringe-based products. Furthermore, V-OVS® and V-OVS®
next share the same contact materials and a range of industry standard
tip cap rubber formulations, making it easy to upgrade to the new system as a lifecycle
measure for existing drugs or a differentiating factor for new drugs.
About Vetter Vetter is a
leading Contract Development and Manufacturing Organization (CDMO) with
headquarters in Ravensburg, Germany, and production facilities in Germany,
Austria, and the US. As a global player, the independent pharmaceutical service
provider is also present in the Asia-Pacific markets of Japan, China, South
Korea and Singapore with sales locations. Around the world, small and large
renowned pharma and biotech companies rely on the decades of experience, high
quality, modern technologies, reliability, and commitment of its more than
7,300 employees. In close partnership with its customers, the Vetter team
supplies patients all over the world with medicines, many of which are vital.
The CDMO provides support from drug product development through clinical and
commercial filling to a wide range of assembly and packaging services for
vials, syringes, and cartridges. With innovative solutions, Vetter develops
prefilled drug-delivery systems together with its customers to continuously
improve patient safety, comfort, and compliance. The company is an industry
pioneer in sustainability and a socially and ethically responsible corporate
citizen. The CDMO is a member of the UN Global Compact and Science
Based Target initiative (SBTi) and received platinum status in the renowned
EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, Frost
& Sullivan Customer Value Leadership Award and the recognition
as Best Managed Company emphasize Vetter’s commitment to sustainable
business. Founded in Ravensburg in 1950, the company remains family-owned to
this day. For more information, visit www.vetter-pharma.com and follow Vetter on LinkedIn.
Contact Vetter Pharma International GmbH Markus Kirchner Corporate Spokesperson / Media Relations Eywiesenstrasse 5 88212 Ravensburg Germany Phone: +49 (0)751-3700-3729 E-mail: PRnews@vetter-pharma.com
©
Vetter Pharma International GmbH: V-OVS® next mounted on a
syringe